or
forgot password

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma


Phase 2
18 Years
75 Years
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma


To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide
and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous
stem cell rescue in the treatment of multiple myeloma.


Inclusion Criteria:

- received cytoreduction prior to transplant

- adequate organ function

Exclusion Criteria:- previous transplant

- smoldering MM or benign monoclonal gammopathy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Toxicity and efficacy of sequentially administered high dose chemotherapy and autologous hematopoietic cell transplantation

Outcome Time Frame:

Patients will have a daily CBC with platelet count, and chemistries until engraftment, then as indicated clinically. Chest x-rays will be done weekly until engraftment, then as indicated clinically. Patients will be restaged for abnormal proteins (SPIE)

Safety Issue:

Yes

Principal Investigator

Sally Arai

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT27

NCT ID:

NCT00186238

Start Date:

September 1994

Completion Date:

April 2010

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317